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Cerebrospinal fluid CXCL13 as a diagnostic
marker of neuroborreliosis in children: a
retrospective case-control study
M. M. Remy1*†, N. Schöbi2†, L. Kottanattu2, S. Pfister1, A. Duppenthaler2 and F. Suter-Riniker1
Abstract
Background: Lyme neuroborreliosis (LNB) is a frequent manifestation of Lyme disease in children and its current
diagnosis has limitations. The elevation of the chemokine CXCL13 in the cerebrospinal fluid (CSF) of adult patients
with LNB has been demonstrated and suggested as a new diagnostic marker. Our aim was to evaluate this marker
in the CSF of children with suspected LNB and to determine a CXCL13 cut-off concentration that would discriminate
between LNB and other central nervous system (CNS) infections.
Methods: For this single-center retrospective case-control study we used a diagnostic-approved ELISA to measure
CXCL13 concentrations in the CSF of 185 children with LNB suspicion at presentation. Patients were classified into
definite LNB (cases), non-LNB (controls with other CNS affections), and possible LNB. A receiver-operating characteristic
curve was generated by comparison of cases and controls.
Results: CXCL13 was significantly elevated in the CSF of 53 children with definite LNB (median 774.7 pg/ml) compared
to 91 control patients (median 4.5 pg/ml, p < 0.001). A cut-off of 55 pg/ml resulted in a sensitivity of 96.7%
and a specificity of 98.1% for the diagnosis of definite LNB and the test exhibited a diagnostic odds ratio of
1525.3. Elevated CSF CXCL13 levels were also detected in three controls with viral meningitis (enterovirus
n = 1, varicella-zoster virus n = 2) while other CNS affections such as idiopathic facial palsy did not lead to
CXCL13 elevation. Of the 41 patients with possible LNB, 27% had CXCL13 values above the cut-off of 55 pg/
ml (median 16.7 pg/ml).
Conclusions: CSF CXCL13 is highly elevated in children during early LNB as previously shown in adults. CXCL13 is a
highly sensitive and specific marker that helps to differentiate LNB from other CNS affections in children.
Keywords: CXCL13, Lyme neuroborreliosis, Cerebrospinal fluid, Antibody index, Sensitivity, Specificity
Background
Lyme disease is the most common vector-borne disease in
the Northern Hemisphere [1, 2]. It is caused by Borrelia
burgdorferi sensu lato spirochetes [3], which are transmit-
ted to humans by ticks. Early Lyme neuroborreliosis (LNB)
is a frequent manifestation of Lyme disease in children [4].
It presents a few weeks to months (mostly 4–6 weeks) after
a tick bite with neurological deficit, i.e., aseptic meningitis,
radiculitis, or loss of function of cranial nerves [5]. The
most common neurological manifestations of LNB in
European children are acute facial nerve palsy (55–61%),
other cranial nerve palsies, and lymphocytic meningitis
(27%) [4–8]. Signs and symptoms of early LNB typically
last for less than 6 months, and the natural course of the
disease is often self-limiting [9].
Laboratory confirmation of LNB is hampered by the
low yield of bacterial culture and the poor sensitivity of
polymerase chain reaction (PCR) in the cerebrospinal
fluid (CSF) [10, 11]. According to the case definition of
the European Federation of Neurological Societies
(EFNS) [12], intrathecal production of antibodies against
Borrelia burgdorferi (B.b.) must be proven to confirm
the diagnosis of definite LNB. Therefore determination
of Borrelia-specific antibody index (AI) in the CSF has
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become the traditional diagnostic gold standard, despite
limitations such as low sensitivity in the very early phase
of the disease [5, 13, 14] and persistence for years after
eradication of the infection [15, 16]. In addition, it was
shown that up to 20% of patients with proven Borrelia
burgdorferi infection have negative AI [17]. In such cases
when suspicion of neuroborreliosis persists, a serocon-
version in serum has to be demonstrated after 6 weeks
to confirm the diagnosis of LNB [12], causing uncertain-
ties for patients and delaying treatment. Furthermore,
early antibiotic therapy can also affect the humoral re-
sponse and IgM-IgG switch resulting in negative-specific
AI and negative serum IgG [17]. Additional biomarkers
with high sensitivity and specificity are therefore neces-
sary to improve diagnostic procedures.
Recently, measurement of the chemokine CXCL13 in
CSF samples of suspected LNB patients has been iden-
tified as a new potential diagnostic tool [18–28].
CXCL13 is a B-cell chemoattractant expressed in sec-
ondary lymphoid organs including the central nervous
system (CNS) [29]. It is synthesized in early LNB in
considerable amounts into the CSF alongside less clin-
ically relevant chemokines and cytokines [28, 30–32].
CXCL13 promotes the secretion of cytokines that facili-
tate humoral reactions and migration of B lymphocytes
and plasma cells into the CSF [18]. During LNB, B-cells
reaches up to 80% of total cells in CSF, clearly exceed-
ing other CNS infections and inflammatory diseases
[29, 33, 34]. Accordingly, a strong up-regulation of
CXCL13 was observed in the CSF of early LNB patients
and not for other etiologies of CNS inflammation [20, 23].
In contrast, no correlation between blood levels of
CXCL13 and early LNB was demonstrated [35]. CSF
CXCL13 elevation could even be detected before the
intrathecal production of B.b.-specific antibodies, confirm-
ing the key role of this chemokine in B-cell migration to
the infected CNS [22, 26]. By comparing CXCL13 levels
in the CSF of patients with early LNB or with other CNS
inflammatory diseases, several studies have determined
CXCL13 cut-off levels for the diagnosis of early LNB.
These cut-offs vary between 61 pg/ml and 1229 pg/ml [20,
21, 23, 25, 27] and were mostly determined for adult pa-
tients with inclusion of few pediatric patients [21]. More
studies are therefore required to find a universal cut-off
and to firmly establish the diagnostic value of CSF
CXCL13 in LNB, especially in children.
The objective of our study was to evaluate the clinical
relevance of measuring CXCL13 in the CSF of children
with suspected LNB in the endemic region of Bern,
Switzerland, and to establish a cut-off value for the diag-
nosis of early LNB in children. Using specific antibody
index as a gold standard, we compared concentrations
of CXCL13 among CSF samples of patients with definite
LNB, possible LNB, and non-LNB controls.
Methods
Setting and patients
This is a single-center retrospective case-control study in
the endemic region of Bern, Switzerland, over the period
of January 2012 to December 2016. Children (0 to 18 years
of age) with suspicion of neuroborreliosis and for whom
frozen CSF samples were available, were retrospectively
identified using the electronic database of the Institute for
Infectious Diseases of the University of Bern, Switzerland.
Clinical data were obtained from the archived charts
or the electronic database of the Children’s University
Hospital Bern, Switzerland. Patients were divided into
the following subgroups according to the European
Federation of Neurological Societies (EFNS) guidelines
[12]: definite LNB (cases), non-LNB (controls), and
possible LNB.
Definite LNB was diagnosed using the following cri-
teria: (i) patients had symptoms consistent with LNB
and other relevant differential diagnoses were excluded,
(ii) presence of mononuclear pleocytosis (total cell count
>5/μl), and (iii) intrathecal production of Borrelia-
specific antibodies. Possible LNB was diagnosed if only
two out of three criteria were fulfilled. When less than
two criteria or when a relevant differential diagnosis was
present, LNB was excluded and the case was moved to
the control group (non-LNB). Relevant differential diag-
noses were defined as: spondylodiscitis, Guillain-Barré
syndrome, mastoiditis, hereditary neuropathy, muscular
atrophy, stroke, esophoria, erythromelalgia, infections
with enterovirus, tick-borne encephalitis virus (TBEV),
or varicella-zoster virus (VZV). Patients with malignan-
cies or with CNS symptoms longer than 6 months were
excluded from the study. LNB symptoms were defined
by one or several of the following symptoms: facial palsy,
headache, cranial nerve palsy, meningism, radiculitis,
myelitis, ataxia, hemiparesis, fever, blurred vision, and
cauda equina syndrome. Known antibiotic pre-treatment
was not considered an exclusion criteria since patients
who received antibiotics prior to lumbar puncture were
not exhaustively identified in our data bank.
CSF and serum laboratory analyses
Routine CSF and serum laboratory analyses were per-
formed at the University of Bern, Switzerland, respectively,
in the Center for Laboratory Medicine (cell count, pro-
tein) and in the Institute of Infectious Diseases (serology
and antibody index). Serum and CSF samples were subse-
quently stored at −20 °C at the Institute of Infectious Dis-
eases. A screening test for Borrelia was first performed on
fresh serum samples using enzyme-linked immunosorbent
assays (ELISA) for IgG and IgM (recomWell, Mikrogen,
or Virion/Serion) according to the manufacturer’s instruc-
tions. In case of positive screening test or persistent suspi-
cion of early neuroborreliosis, CSF/serum antibody index
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was determined. In this case, the presence of Borrelia-
specific antibodies in simultaneously sampled serum and
CSF probes was determined using IgG and IgM ELISA
according to the manufacturer’s instructions. Two differ-
ent ELISA kits were used over the period of the present
study (IDEIA, OXOID until May 2014, and Virion/Serion
after June 2013). The antibody index (AI) was considered
positive when ≥0.3 (IDEIA, OXOID) or when ≥1.5 (Vir-
ion/Serion).
CSF CXCL13 concentrations were measured by the
first diagnostic-approved CXCL13 ELISA (EUROIM-
MUN AG, Luebeck, Germany) according to the manu-
facturer’s instructions. CSF samples which had been
stored for maximum 3 years at −20 °C were allowed to
thaw at room temperature and measurements were per-
formed neat in duplicates (intra-assay variation coeffi-
cients <15%). In a few cases, a dilution 1:5 was needed
to analyze the samples due to low available volume; this
had no influence on the test result. Incubations were
done at room temperature. CXCL13 values below the
detection limit of 4.6 pg/ml were assigned a value of
4.5 pg/ml. When optical density (OD) values exceeded
the OD value of the highest standard, samples were fur-
ther diluted 1:10 and 1:100 to obtain accurate concentra-
tions of CXCL13. Results were obtained within 4 h.
Statistics
Statistical analyses and ROC curves were performed
using GraphPad Prism 6.0 (GraphPad Software, San
Diego, USA). Diagnostic test evaluation was performed
using MedCalc online calculator (MedCalc Software,
Ostend, Belgium). Data are presented as a median
(range) value or a number (%) value. Comparison of
means was performed using non-parametric Mann-
Whitney test. P values <0.05 were considered significant.
Results
Patients
Initially, 207 children with suspicion of Lyme neurobor-
reliosis at presentation were retrospectively identified for
the present study, of which 22 had to be excluded due to
malignancy or prolonged symptom duration. The
remaining 185 patients were retained, and their CSF was
analyzed for CXCL13. Details on sex, age, clinical pres-
entation, and duration of symptoms until diagnostic
lumbar puncture are presented in Table 1. After routine
analyses, 53 patients (29%) were diagnosed with “definite
LNB,” i.e. positive antibody index (AI), CSF pleocytosis
(CSF cell count >5 cells/μl), and neurological symptoms
[12] while 91 patients (49%) were classified as controls
in a “non-LNB” group (negative AI and no pleocytosis
or presence of a differential diagnosis). Some of these
control patients had viral meningitis or encephalitis due
to varicella-zoster virus (VZV, n = 4), enterovirus
(n = 20), or tick-borne encephalitis virus (TBEV, n = 5),
while others had inflammatory diseases (n = 8), idio-
pathic facial palsy (n = 19), primary headache (n = 11),
or other diseases (n = 29). Inflammatory diseases in-
cluded three Guillain-Barré Syndrome, three retrobulbar
optic neuritis, one acute disseminated encephalomyelitis
(ADEM), and one parainfectious brainstem encephalitis.
Forty-one additional patients (22%) were classified as
“possible LNB” as they fulfilled only two out of three cri-
teria for LNB [12]. This included 27 patients with pleo-
cytosis and a negative AI, 13 patients with pleocytosis
and no AI (not performed due to negative serology or
lack of material), and 1 patient with a positive AI and no
pleocytosis. In these cases, no final diagnosis could be
established.
Diagnostic evaluation of CSF CXCL13 in patients with
definite LNB versus non-LNB
The median CXCL13 concentration in the CSF of pa-
tients with definite LNB was 774.7 pg/ml and values
ranged from 58.9 to 13487.0 pg/ml with 1 outlier at
4.5 pg/ml (Table 2 and Fig. 1a). In comparison, non-
LNB patients including patients with other confirmed
CNS diseases had a median CSF CXCL13 concentration
of 4.5 pg/ml (range 4.5–816 pg/ml). Means were highly
significantly different (p < 0.001, Fig. 1a).
To assess the diagnostic performance of CXCL13, a
receiver-operating characteristic (ROC) curve was drawn
for cases (definite LNB) versus controls (non-LNB,
Fig. 1b). The optimal cut-off for the diagnosis of definite
LNB was 55 pg/ml with a sensitivity of 96.7% and a spe-
cificity of 98.1% (Table 3). The positive and negative like-
lihood ratios [36, 37] of the CSF CXCL13 test were,
respectively, 29.8 and 0.02 resulting in a high diagnostic
odds ratio of 1525.3 [38].
CSF CXCL13 in controls and possible LNB cases
Within the 91 patients of the “non-LNB” group, only 3
patients (3%) had a CSF CXCL13 concentration above
the 55 pg/ml cut-off (Table 2, Fig. 2). Two of these pa-
tients were diagnosed with varicella by PCR amplifica-
tion in the CSF and their CXCL13 levels were 239.9 and
145.1 pg/ml. In contrast the other two patients with
VZV had very low CXCL13 concentrations (11.7 and
4.5 pg/ml). One patient with enterovirus infection also
had a highly elevated level of CXCL13 (816.1 pg/ml)
while the other 19 cases of enteroviral infection showed
low CSF CXCL13 concentrations with a maximum of
29.3 pg/ml (median 5.8 pg/ml). Median CXCL13 con-
centrations in the CSF of patients with TBEV was
8.7 pg/ml while inflammatory diseases, facial palsy of
unknown origin, primary headache, and other diseases
had median CXCL13 levels of 4.5 pg/ml.
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In the possible LNB group, CXCL13 concentrations
ranged from 4.5 to 1418.6 pg/ml (Table 2, Fig. 3). Pa-
tients were subdivided according to pleocytosis and AI
availability. Most of them exhibited pleocytosis together
with a negative AI (n = 27), of which nine (33%) had
elevated CSF CXCL13 concentration. Another group of
13 possible LNB patients had pleocytosis but no de-
termined antibody index due to a negative serology
at initial work-up (in 92%, Table 1) and/or due to
lack of material. Two (15%) of these 13 patients
showed elevated levels of CXCL13 (Table 2, Fig. 3).
The only patient with a positive index and no pleo-
cytosis had a low CSF CXCL13 concentration
(13.9 pg/ml). Possible LNB patients predominantly
presented with headache along with meningitis
(49%), acute facial palsy (20%), or other cranial
nerve palsies (10%, Tables 1 and 4). None of these
symptoms were associated with a clear CXCL13 pat-
tern (Table 4). Results of CSF examination (Table 1)
were highly variable but a lower percentage of
mononuclear cells (<74%) was associated with a
negative CSF CXCL13 result (Table 4). Also, patients
presenting with symptoms with a duration of 5–7 days
were for 73% positive for CXCL13 (Table 4). No
other microorganisms could be found to confirm or
Table 2 CXCL13 concentrations in different disease groups
AI Pleo. n CXCL13a (pg/ml) CXCL13>COb
Definite LNB + + 53 774.7 (4.5–13487) 52 (98)
Possible LNB 41 16.7 (4.5–1418.6) 11 (27)
AI neg. − + 27 25.0 (4.5–384.1) 9 (33)
AI nd. nd + 13 8.1 (4.5–1418.6) 2 (15)
AI pos. + − 1 13.9 0 (0)
Non-LNB 91 4.5 (4.5–816.1) 3 (3)
VZV − −/+ 4 78.4 (4.5–239.9) 2 (50)
Enterovirus − −/+ 20 5.8 (4.5–816.1) 1 (5)
TBEV − + 5 8.7 (6.7–19.9) 0 (0)
Inflammatory − − 8 4.5 (4.5–21.1) 0 (0)
Facial palsy − − 19 4.5 (4.5–14.6) 0 (0)
Headache − − 11 4.5 (4.5–7.4) 0 (0)
Others − − 24 4.5 (4.5–50.4) 0 (0)
Total 185 10.4 (4.5–13487) 66 (36)
The “Inflammatory” group included three Guillain-Barré syndrome, three retro-
bulbar optic neuritis, one acute disseminated encephalomyelitis (ADEM), and
one parainfectious brainstem encephalitis
CO cut-off determined at 55 pg/ml in our study, LNB Lyme neuroborreliosis, AI
antibody index, Pleo. pleocytosis (>5 cells/ul in CSF), n numbers, neg. negative,
nd not determined, pos. positive, VZV varicella-zoster virus, TBEV tick-borne
encephalitis virus
aData are presented as median (range)
bData are presented as number (%)
Fig. 1 Diagnostic value of CSF CXCL13 in patients with definite LNB versus non-LNB. a CXCL13 concentrations in the CSF of pediatric patients
with definite LNB versus control non-LNB patients. Black lines indicate medians. Values lower than the detection limit were arbitrarily assigned a
value of 4.5 pg/ml. The dashed line indicates the optimal cut-off at 55 pg/ml. LNB Lyme neuroborreliosis. Means were compared by a Mann-
Whitney test. ***P < 0.001. b Receiver-operating characteristic (ROC) curve of CSF CXCL13 levels from definite LNB patients versus control non-
LNB patients. The dashed line indicates the optimal cut-off at 55 pg/ml. AUC area under the curve (95% confidence interval)
Table 3 Accuracy of CSF CXCL13 test to diagnose definite LNB
in children using a 55 pg/ml cut-off
Sensitivity % 96.7 (90.7–99.3)
Specificity % 98.1 (89.9–100.0)
Positive LR 29.8 (9.8–90.6)
Negative LR 0.02 (0.0–0.14)
Diagnostic odds ratio 1525.3 (154.6–15047.4)
Definite LNB cases (n = 53) were compared to control non-LNB cases (n = 96)
LR likelihood ratio. 95% confidence interval is indicated in parentheses
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infer LNB suspicion in these 41 patients with uncer-
tain diagnosis.
Discussion
We demonstrate that CXCL13 is highly elevated in the
CSF of children with definite LNB and confirm previous
findings in adult and mixed population [18–28]. By
comparison with pediatric patients bearing similar
CNS symptoms, we show that the human diagnostic-
approved CXCL13 ELISA (Euroimmun) has a very high
diagnostic performance (odds ratio 1525.3, [38]) for the
diagnosis of early LNB with a cut-off at 55 pg/ml.
In the literature, cut-offs range from less than 100 to
more than 1229 pg/ml and were determined using a
similar but not diagnostic-approved CXCL13 ELISA
(Quantikine, R&D). A cut-off at 250 pg/ml had been
twice suggested [23, 26]. The studies, however, included
mostly adult patients with very different symptoms, i.e.,
asymptomatic HIV, bacterial meningitis, or conditions
that also result in a CSF CXCL13 increase, i.e., neuro-
syphilis or Cryptococcus neoformans infections [25]. This
might have led to the difference in cut-off compared to
our pediatric study. Recently, Pícha et al. [27] have
strictly compared LNB adult patients to patients with
aseptic non-borrelial CNS infections, and their lowest
proposed cut-off was 29 pg/ml with a sensitivity of 90%
and a specificity of only 72%. Contrary to our study,
both definite and possible LNB cases were included in
the cases numbers to determine this cut-off and elevated
CXCL13 values in the non-LNB group were not
discussed.
Within our definite LNB cases, only one patient had a
CSF CXCL13 concentration lower than the defined cut-
off of 55 pg/ml. She was a 3-year-old girl who was
Fig. 2 CSF CXCL13 concentrations in various control groups. Non-LNB
patients were further classified in various disease groups according to the
presence of a differential diagnosis. Definite LNB patients are shown for
comparison. Black lines indicate medians. Values lower than the detection
limit were arbitrarily assigned a value of 4.5 pg/ml. The dashed
line indicates the optimal cut-off at 55 pg/ml. The “Inflammatory”
group included three Guillain-Barré syndrome, three retrobulbar
optic neuritis, one acute disseminated encephalomyelitis (ADEM),
and one parainfectious brainstem encephalitis. VZV varicella-
zoster virus, TBEV tick-borne encephalitis virus
Fig. 3 CSF CXCL13 concentrations in possible LNB patients. Patients
with uncertain diagnosis of LNB according to the EFNS guidelines
[12] and lacking a final differential diagnosis were regrouped in a
possible LNB group which was subdivided according to antibody
index and pleocytosis data. nd not determined. Black lines indicate
medians. Values lower than the detection limit were arbitrarily
assigned a value of 4.5 pg/ml. The dashed line indicates the optimal
cut-off for the diagnosis of definite LNB at 55 pg/ml
Table 4 CXCL13 results in the possible LNB group according to
various baseline characteristics
n (%) CXCL13 > CO
Possible LNB 41 (100) 11 (27)
Leading symptoms
Facial palsy 8 (20) 2 (25)
Headache 20 (49) 7 (35)
Cranial nerve palsy 4 (10) 1 (25)
Mononuclear cells
≥74% 32 (78) 11 (34)
<74% 8 (20) 0 (0)
Symptoms duration
<5 days 22 (54) 2 (9)
5–7 days 11 (27) 8 (73)
>7 days 8 (20) 1 (13)
Data are presented as number (%). CO cut-off determined at 55 pg/ml in our
study, LNB Lyme neuroborreliosis
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treated for an erythema migrans with amoxicillin 2 weeks
before the onset of an acute facial palsy. She had a posi-
tive AI but a low CSF cell count of eight cells per micro-
liter and her CXCL13 value was 4.5 pg/ml. It is known
that CSF CXCL13 levels quickly decline after the initi-
ation of an antibiotic treatment with ceftriaxone or
doxycycline [25, 39, 40]; whether amoxicillin has a com-
parable effect is unknown and needs further evaluation.
Similarly, the only “possible LNB” patient with a positive
index and no pleocytosis had been treated with amoxi-
cillin 11 days before lumbar puncture, which could
explain the lack of pleocytosis as well as the low CSF
CXCL13 concentration (13.9 pg/ml). In children, anti-
biotic treatments are frequently used in case of febrile
infections and the likelihood for a coincidence of antibi-
otics pre-treatment with the onset of early LNB is high.
In our retrospective study, however, these treatments
were poorly documented, constituting a limitation to
our results’ interpretation. CXCL13 values in our defin-
ite LNB patients might also be lower than in other stud-
ies where only untreated LNB patients were included.
Long-term storage of CSF samples could in theory affect
chemokine concentrations too. Previous studies have,
however, reported good stability of CSF CXCL13 over
repeated freeze-thaws and in CSF samples kept frozen
for up to 5 years [23, 25].
Patients with possible LNB and a negative AI had a
very short history of symptoms (median 3 days), com-
pared to 9 days for patients with definite LNB. Such
short symptoms durations could explain the lack of
intrathecal antibody production [17, 20] and highlight
the benefits of measuring CXCL13 in extremely early
cases. In adults, CXCL13 could indeed be detected very
early and sometimes even before pleocytosis occurred
[22, 26].
Our study also shows for the first time the expected
percentage of mononuclear cells in the CSF of children
with definite LNB (median 98.5%, range 74–100%,
Table 1). Concordantly, all possible LNB patients with
less than 74% mononuclear cells had a negative CSF
CXCL13 result (Table 4), hence virtually excluding true
LNB according to the low negative likelihood ratio of
the test.
Concerning controls, CSF CXCL13 concentrations
were elevated in two cases of varicella-zoster virus and
one case of enterovirus infection, both of which were de-
tected in the patients’ CSF by PCR. Borrelia serology at
presentation was negative for these three patients and
for the enterovirus case it was still negative 6 weeks after
the onset of symptoms, excluding a concomitant Borre-
lia infection. Such a sporadic elevation of CXCL13 in the
CSF of patients with viral meningitis (VZV, enterovirus,
TBEV, herpes simplex virus) had already been observed
in previous studies [19, 20, 23, 25, 26] and probably
reflects a rare transient induction of CXCL13 in the vir-
ally infected CNS. In our 5 pediatric cases of TBEV,
however, CSF CXCL13 remained negative. In the litera-
ture, CSF CXCL13 elevation was also demonstrated for
other diseases such as chronic infections (HIV, neuro-
syphilis) and autoimmune diseases (including multiple
sclerosis or anti-NMDAR encephalitis) [20, 23, 25, 39–
43], which are more prevalent in the adult population
and were not represented in our study; as well as CNS
lymphomas and some bacterial infections [19, 20, 44],
which show a very different clinical picture and were not
included in our study.
The strength of the CXCL13 diagnostic test (Table 3)
was determined for confirmed definite LNB cases in
comparison to non-LNB controls and therefore should
help refine the diagnosis in uncertain cases of LNB sus-
picion. Within all possible LNB cases, 27% of patients
exhibited elevated CSF CXCL13 concentrations, which
corresponds to a high likelihood of true LNB (Table 3).
According to the EFNS guidelines, a positive serology
for Borrelia would however be needed 6 weeks later in
order to confirm the diagnosis of neuroborreliosis in
these uncertain possible LNB cases with a negative AI.
This was not routinely performed in our retrospectively
studied population and could only be confirmed in 1 out
of 11 cases; a lack of data which clearly limits the inter-
pretation of our results. Since no other microorganisms
could be found in these patients early LNB therefore
remained a highly likely but unconfirmed diagnosis.
Such cases will be further examined in a prospective
study.
CSF CXCL13 test would be especially helpful in an
emergency setting when children present with acute
facial palsy or headache and meningitis (Table 4).
Acute facial palsy is the most common finding in
European children with early LNB [4, 8]; however, its
first differential diagnosis is idiopathic facial palsy as
40–75% of pediatric unilateral facial paralysis have
unknown etiology [45, 46]. In our controls, we had
19 cases of idiopathic cases which all showed negative
CSF CXCL13 (Fig. 2, Table 2), reinforcing the
strength of the CXCL13 diagnostic test in uncertain
cases of facial palsy. Regarding pediatric emergencies,
CSF CXCL13 diagnostic test also requires less bio-
logic material and has faster turn-around time com-
pared to the AI. As little as 150 μl of CSF and 4 h
are needed to complete the test compared to 800 μl
and up to several days for the AI.
Conclusions
Our study on children with LNB symptoms supports
previous findings in adults showing a high diagnostic
performance of CSF CXCL13 for definite LNB cases, es-
pecially in case of negative serology, negative AI, or
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impossibility to perform the AI. The excellent negative
likelihood ratio of the test (0.02) combined with pre-test
probabilities should enable rapid exclusion of LNB in
case of negative CSF CXCL13 results and absence of
previous antibiotic treatment, while the high positive
likelihood ratio (29.8) will also give a strong diagnostic
lead [36, 37]. Therefore, we recommend the systematic
use of the CXCL13 diagnostic-approved ELISA in chil-
dren to help clinicians in taking prompt decisions re-
garding treatment.
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